Several studies demonstrated the beneficial effects of the therapeutic targeting of IBP signaling at the level of farnesyl diphosphate synthase (FDPS), which can be inhibited by bisphosphonates (BP) or nitrogen bisphosphonates (NPBs), the drugs most commonly used in the management of MM bone disease, acting by reducing bone resorption and increasing bone density through inhibition of osteoclast activity [103]. This evidence concerns the gene FDPS and Miyoshi myopathy.